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ABSTRACT
VASCULAR AND HEMODYNAMIC PARAMETERS FOLLOWING ACUTE EXERCISE
AND ANTIOXIDANT SUPPLEMENTATION
(May 2010)
Rebecca Marie Kappus, B.S., The University of Toledo
M.S., Appalachian State University
Chairperson: Scott Collier
Objective: The objective of this study was to investigate the potential additive effects
of the multi-flavonoid plus fish oil combination and aerobic exercise on post exercise
hypotension (PEH). We hypothesize that the use of a multi-flavonoid plus fish oil
supplement in combination with aerobic exercise will show an additive effect on favorable
blood pressure (BP) and pulse wave velocity (PWV) changes while increasing arterial
distensibility. Design: Hemodynamic and vascular measurements were performed pre and
post exercise and before and after double blinded placebo or supplementation of 1000 mg
quercetin (Q) with 120 mg epigallocatechin 3-gallate (EGCG), 400 mg isoquercetin, and 400
mg omega-3 fatty acids from fish oil (Q-EGCG). Setting: Visits took place at the Vascular
Biology and Autonomic Studies lab or the Human Performance lab at Appalachian State
University. Participants: 20 young, healthy, pre-hypertensive subjects not on any
medication, including aspirin or birth control, and without known cardiovascular disease,
diabetes, or hypertension were recruited. Interventions: Two weeks of Q-EGCG or placebo.
Main Outcomes: The dependent variables in this study were PWV, BP, Pulse wave analysis
(PWA), Augmentation index (Alx) and ORAC and FRAP levels. Results: No significant
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differences were found in PWV (central or peripheral), resting systolic blood pressure (SBP),
diastolic blood pressure (DBP) or ORAC. There were significant differences found in Alx,
FRAP and BP from pre to post supplementation in the post exercise SBP measurements.
Conclusions: Two weeks of supplementation on Q-EGCG produced significant decreases in
Alx, post exercise SBP and an increase in FRAP.
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Chapter 1
Introduction
Hypertension is a chronic medical condition in which there is an elevation in blood
pressure (BP) of 140/90 mmHg or above (Chobanian et aI., 2003) and is considered to be a
risk factor for cardiovascular disease (Cockcroft, Webb, & Wilkinson, 2000). Untreated
hypertension is a risk factor for stroke, heart attacks, heart failure and arterial aneurysm and
is the leading cause of renal failure (Pierdomenico et aI., 2009). Epidemiological studies
have shown that individuals with untreated, severely high blood pressure (250/130 mm Hg)
can expect to live no more than a few years unless medically treated (Guyton & Hall, 2005).
Beginning at a systolic pressure of 115 mmHg and a diastolic pressure of75 mmHg,
cardiovascular disease risk doubles for each increment of 20/1 0 mmHg (Chobanian et aI.,
2003). In addition, the prevalence ofchildhood hypertension in increasing (Honzikova et aI.,
2006) and regardless of age onset, early detection is important to begin a treatment plan that
could prevent long term damage (Gan, Loh, & Seet, 2003).
Following an acute bout ofexercise, there is a drop in blood pressure, and chronic
exercise leads to a more sustained fall in BP. Post-exercise hypotension (PEH) can be
defined as a sustained reduction in blood pressure in both normotensive and hypertensive
subjects following a bout of exercise. The length of the hypotensive response in individuals
with pre-to stage-one hypertension (> 120/80 mm Hg) can last up to 24 hours, comparatively,
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in normotensives the PEH response typically lasts 1 hour (Halliwill, 2001). It is generally
agreed that PEH reflects a fall in peripheral vascular resistance that is not completely offset
by an increase in cardiac output in the post-exercise period (Halliwill, 2001). Numerous
studies have confirmed the existence of PEH in normotensive and hypertensive individuals
and in various animal models (Halliwill, 2001; KelU1ey & Seals, 1993; MacDonald, 2002;
Martin, Dubbert, & Cushman, 1990; Rossow et aI., 2010).
The reduction in peripheral vascular resistance is mediated by nitric oxide (NO),
adenosine, and the alteration of sympathetic outflow. NO, also known as endothelium-
derived relaxing factor (EDRF), acts as a potent vasodilator by promoting vascular smooth
muscle relaxation, which can reduce vascular resistance to blood flow, therefore decreasing
blood pressure (Boone & Corry, 1996). NO expression has been shown to be upregulated
following exercise, due to rapid blood flow through arteries causing shear stress on the
endothelial cells, which use NO to signal to the surrounding smooth muscle to relax,
resulting in vasodilation (Guyton & Hall, 2005). Reductions in NO bioavailability may be
caused by decreased expression of the endothelial cell NO synthase (eNOS), a deficiency of
substrate or cofactors for eNOS, modification of cellular signaling so that eNOS is not
activated, or NO degradation by reactive oxygen species (ROS, i.e.: oxidative stress) (Cai &
Harrison, 2000). Exogenous antioxidant supplementation has been shown to reduce
inflammation and oxidative stress, which will increase the bioavailability of NO (Barton, Ni,
& Vaziri, 2001; Eiserich, Butler, van der Vliet, Cross, & Halliwell, 1995; Forstermann,
Boissel, & Kleinert, 1998; Kingwell, 2000; Ohta, Nanri, Matsushima, Sato, & Ikeda, 2005)
and recent studies have shown that antioxidants can reduce blood pressure (Edwards et aI.,
2007). Flavonoids in particular are strong antioxidants due to their low redox potential and
2
capacity to donate several electrons or hydrogen atoms. They consist of a group of
polyphenolic substances that occur naturally in fruits, vegetables, grains, herbs, tea and fruit
juices. The most widespread of all flavonoids is quercetin, an antioxidant with a variety of
bioactive effects including anti-inflammatory, anti-pathogenic, anti-oxidant, and
immunoregulatory influences. Quercetin supplementation in high dosages for an extended
period of time has not been linked to any adverse effects in humans or rodents, and some
researchers suspect a high quercetin intake from food may reduce risks of ischemic heart
disease, type 2 diabetes, asthma, and various types of cancer including lung, colorectal,
pancreatic, and prostate (Nieman et aI., 2009). There are few studies that have investigated
the effects of antioxidants on human vasculature, and to this author's knowledge, no studies
have investigated the effects of a multi-flavanoid and fish-oil supplement with or without
exercise intervention.
The current study investigated hemodynamic and vascular responses and blood
antioxidant levels following a 2-week multi-flavonoid and fish oil supplement or placebo in
20 young healthy males and females (18-26 y) without known cardiovascular disease. All
subjects underwent hemodynamic and vascular measurements before and after exercise as
well as prior to, and following a 2 week oral supplementation regimen of the compounded
multi-flavonoid and fish oil supplement.
Statement of the Problem
Hypertension is a risk factor for stroke, myocardial infarction, heart failure and
arterial aneurysm and is the leading cause of renal failure (Pierdomenico et aI., 2009).
Finding an effective and non pharmacological treatment for hypertension would help reduce
3
health care costs by the use of exercise and supplementation instead of prescription
medications, which in tum would decrease insurance costs. Therefore, the purpose of this
study was to investigate the potential additive effects of the multi-flavonoid plus fish oil
supplement and aerobic exercise on post-exercise blood pressure and arterial homeostasis.
Hypothesis
We hypothesize that the use ofa multi-flavanoid plus fish oil supplementation in
combination with aerobic exercise will show further decreases in blood pressure during post-
exercise hypotension. Further, we hypothesize that the treatment group will show greater
decreases in pulse wave velocity (PWV) and augmentation index.
Significance of the Study
The pharmacological treatment of hypertension can be costly and in some cases
ineffective, and produce many negative side effects (Collier, 2008). Due to the increasing
numbers of hypertensive individuals, there has been a substantial increase in costs pertaining
to diagnosing and treating hypertension. This study provides clinical and economical value
since hypertensives could possibly reduce their blood pressure with supplementation and
exercise. It also could reduce the dependency of hypertensive individuals on medication,
which can be unsuccessful and have multiple negative side effects. Not only could exercise
and antioxidant supplementation be a treatment, but this treatment may also be used as a
preventative measure.
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Definition of Terms
(Berne, 2001; Brooks G, 2000)
Blood pressure (BP) - the pressure exerted by the blood on the walls of the blood vessels.
Systolic blood pressure (SBP) - the highest pressure in the arteries during the contractile
phase of the cardiac cycle
Diastolic blood pressure (DBP) - the lowest pressure during the resting phase of the cardiac
cycle
Baroreceptor Reflex - One of the body's mechanisms for maintaining blood pressure. It is a
negative feedback loop in which an elevated blood pressure causes a decrease in vasomotor
tone due to an increase in relaxing factors. A decreased blood pressure depresses the
baroreflex, causing blood pressure to increase.
Mean arterial pressure (MAP) - the average arterial pressure during a single cardiac cycle and
can be approximated by the equation MAP = DBP + 1/3(SBP-DBP)
Arterial distensibility (AD) - defined as change in an artery's diameter/change in blood
pressure within that artery
Arterial stiffness - Measures of arterial stiffness estimate the artery's ability to expand and
contract with cardiac pulsation and relaxation.
Pulse wave velocity (PWV) - The velocity of travel ofa pressure wave along an artery is
related to the stiffness of an arterial segment between measurement sites. PWV measures
arterial stiffness indirectly since it is influenced by a number of factors, including wall
thickness, vessel radius, or blood density independent of arterial stiffness. PWV = Distance
(m) / time (s)
Augmentation Index (Alx) - The percentage of central pulse pressure (the difference between
systolic and diastolic blood pressure) that is reflected back to the heart, derived with pulse
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wave analysis and BP measurements. Alx is considered to be an index that is linked to
arterial stiffness and cardiac afterload.
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Chapter 2
Literature Review
Hypertension, commonly referred to as elevated blood pressure (2: 140/90 mmHg), is
widely prevalent in the western world and it imposes a massive burden on health care costs in
the United States. The cost of hypertension, both direct and indirect, were estimated to be
$69.4 billion for the year of 2008, making it the second most costly cardiovascular related
disorder (Lynch, Markosyan, Melkonian, Pesa, & Kleinman, 2009). Therefore, it is
important to investigate new pharmacological and non-pharmacological modalities for
treating this problem. Currently, most hypertensives are being treated with some form of
prescription medication. However, non-pharmacological medical treatments are in demand in
order to ease the burden on healthcare and insurance costs in addition to lessening the
negative side effects associated with prescription medications. It is commonly known that an
acute bout ofexercise leads to a decrease in blood pressure (Hamer, 2006), making exercise
an effective treatment for hypertension. In recent literature, antioxidants have been studied
for their effect on blood pressure and have been shown to increase NO levels, reducing
inflammation and oxidative stress (Barton et aI., 2001; Eiserich et aI., 1995; Forstermann et
aI., 1998; Kingwell, 2000). An increase in the bioavailability of NO with a concomitant
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decrease in vascular inflammation leads to augmented levels of vasodilation, subsequently
decreasing systemic blood pressure. Therefore, the purpose of this study is to determine the
effects of a combined exercise and antioxidant supplementation regimen on blood pressure
and pulse wave velocity, when compared to placebo.
Hypertension
Hypertension is an increasing problem in today's society. In 2006, 73.6 million
American adults were affected by hypertension, which increased from 65 million in 2000
(Lynch et aI., 2009) and it is predicted to affect a third of the world's population by 2025
(Hamer, 2006). In 2000, over 150,000 people died from hypertension, which was a primary
or secondary cause attributed in their death (Hajjar, Kotchen, & Kotchen, 2006). When left
untreated, hypertension will increase the risk of coronary artery disease and stroke (Hajjar et
aI., 2006). The disease results from two major factors; elevated cardiac output and/or
increased peripheral resistance and eventually the heart will abnormally remodel and heart
failure risk will increase due to a decrease in left ventricular function (Mayet & Hughes,
2003).
Arterial Stiffness
Healthy large arteries contain elastin, smooth muscle, and collagen, which allow them
to be acquiescent and buffer the pressure change due to ventricular ejection (Cockcroft et aI.,
2000). When degradation occurs in their walls, the arteries are not as compliant and are
unable to absorb the high energy of the blood outflow. Arterial stiffness is the "hardening"'
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or loss of elasticity in the arteries, which can accelerate the atherosclerotic process and is
considered to be a predictor of cardiovascular disease (Maki-Petaja & Wilkinson, 2009).
When arteries lose their elasticity, this reduces their ability to buffer the pressure change in
the cardiac pulse, leading to an increase in systolic blood pressure and a decrease is diastolic
blood pressure, or an overall increase in pulse pressure, which is an important predictor of
cardiovascular risk (Cockcroft et aI., 2000). It is recognized that arterial stiffness results
from a loss of elastin fibers in the vasculature and is modulated by endothelium derived
mediators, such as nitric oxide and endothelin-l. The destruction of elastin leads to the
stiffening of collagen fibers, since the collagen fibers bear the pressure that the elastin can no
longer handle (Maki-Petaja & Wilkinson, 2009). The severity of coronary artery disease is
associated with aortic stiffness (Cockcroft et aI., 2000), and because of this, arterial stiffness
has received increasing attention in recent literature (Kingwell, Berry, Cameron, Jennings, &
Dart, 1997; Williams et aI., 2007). Non-distensible arteries contribute to increased peripheral
resistance, higher pulse pressures and increased ventricular afterload (Benetos et aI., 2002;
Dart & Kingwell, 2001; Kingwell & Gatzka, 2002; Kingwell, Waddell, Medley, Cameron, &
Dart, 2002). This is ofclinical importance because increases in the stiffness of central elastic
arteries such as the carotid and aorta have been associated with increased mortality and
morbidity and is now recognized as independent risk factors for cardiovascular disease
(Mackenzie, Wilkinson, & Cockcroft, 2002).
Arterial stiffness is an important assessment of vascular health and can be measured
noninvasively using pulse wave velocity measurements. When the heart contracts it
generates a pulse or energy wave that travels through the circulation. The velocity of travel
of this pulse wave, measured in meters per second, is related to the time it takes for the pulse
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wave to cover a specific distance, which reflects the stiffness of the arteries. Pulse wave
velocity (PWV) is dependent upon the distensibility of the vasculature (Cockcroft et aI.,
2000), and a higher PWV is indicative of a higher aortic stiffness (less distensibility), which
increases the risk of a cardiovascular event (Mitchell et al.). Distensibility is measured by
PWV using the distance/time equation whereas the pulse wave distance is measured in an
arterial segment and the time travelled by this blood bolus is ascertained by Doppler.
Another important measure of arterial stiffness is the Augmentation Index (AIx)
which is the percentage of the central pulse pressure that is attributed to the refracted pulse
wave. AIx is an estimate of aortic vessel elasticity and is derived by pulse wave analysis
(PWA and BP measurements (Kelly, Hayward, Avolio, & O'Rourke, 1989». Nurnberger et
al. (2002) found that AIx supports a positive correlation with cardiovascular risk and
mortality, which may demonstrate the need for using this measure where measurements of
arterial stiffness can be clinically significant (Nurnberger et aI., 2002).
Sung et al. (2009) studied the effects ofexercise on arterial stiffness among patients
with coronary artery disease and healthy individuals. Arterial stiffness was measured using
pulse wave velocity, and it was shown that following exercise there were significant
decreases in pulse wave velocity, with a larger decrease shown in the patients with coronary
artery disease. However, arterial distensibility measurements (PWV) have not been
measured on normotensive subjects after an acute bout of exercise. Although normotensive
subjects might have some breakdown in the elasticity of their vasculature, it would not be as
pronounced as in hypertensive individuals, so there could potentially be a difference in the
distensibility of arteries post exercise.
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Post Exercise Hypotension
Following an acute bout ofexercise there is a decrease in blood pressure termed post
exercise hypotension (Hamer, 2006). The mechanisms and durations of PEH are not fully
understood, but because of this decrease in SP, PEH has the potential for preventing and
treating hypertension (MacDonald, 2002). Hypertension is less prevalent in people with high
fitness levels due to the effects of chronic exercise on resting blood pressure and reductions
in blood pressure immediately post exercise (Hamer, 2006). Current interventions used to
treat hypertension include pharmacological and psychological therapies, exercise and weight
loss, or any variety of these strategies. By far, the major therapy used is prescription
medication and these medical therapies can have significant negative side effects. Because
of PEH, moderately intense exercise has been studied as a treatment and a prevention of
hypertension that has no long term side effects (Hagberg & Brown, 1995). Even moderately
intense exercise as short as 10 minutes has been shown to decrease resting blood pressure
and also have benefits as a non-pharmacological aid to the treatment of hypertension
(MacDonald, MacDougall, & Hogben, 2000).
Halliwell (2001) confirmed the existence of PEH due to reductions in vascular
resistance mediated by the autonomic nervous system and the release of local vasodilators. It
was shown that PEH was more pronounced and long lasting in people with hypertension.
Hamer (2006) explored differences between acute and chronic mechanisms and showed that
exercise treatment of hypertension should be individualized depending on each person's
response to exercise and level of disease status. Furthermore, it was shown that with exercise
there was a decrease in blood pressure, but it wasn't clear what the intensity, duration, and
frequency of the exercise should be in order to cause this drop in blood pressure. However, a
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recent investigation from Rossow et al. (2010) showed that amongst endurance trained men
and women, the drop in blood pressure following exercise was the same whether high or
moderate intensity exercise was performed.
Acute aerobic exercise leads to a reduction in both systolic and diastolic blood
pressure with a drop of 18 to 20 mm Hg and 7 to 9 mm Hg, respectively, in hypertensives
(Kenney & Seals, 1993). Rueckert et aI. (1996) found that with hypertensive individuals
there was a post exercise hypotensive response that lasted up to two hours after an exercise
bout. Ten minutes after exercise there was a significant decrease from baseline systolic
pressure, mean arterial pressure, total peripheral resistance, and calf vascular resistance.
Systolic blood pressure (SBP) and mean arterial pressure (MAP) were maintained for two
hours post exercise and total peripheral resistance (TPR) returned to baseline within 20
minutes (Rueckert, Slane, Lillis, & Hanson, 1996). However, this study did not examine the
effects ofPEH on normotensive individuals.
Mechanisms
The most influential factor of short term blood pressure control is the baroreflex
feedback loop (Overhaus, Ruddel, Curio, Mussgay, & Scholz, 2003), which are pressure
sensors that regulate BP through a negative feedback loop. Individuals with hypertension
demonstrate cardiac autonomic dysfunction and altered baroreflex sensitivity (BRS)
(Pikkujamsa et aI., 1998). The baroreceptor system adapts to the high pressure within days
by increasing the stimulation threshold of the pressure receptor (AHA, 2003), so
hypertensives develop less sensitive baroreflexes than healthy individuals. Cardiac
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autonomic dysfunction results from changes in adrenergic modulation and dysregulation of
parasympathetic and tonic cardiovascular control, demonstrated by heart rate variability
(HRV) measurements (Lakatta, 1993). The baroretlex in hypertensive individuals also resets
to maintain a higher blood pressure, due to a vagal tone decrease and a sympathetic outtlow
increase (Prakash, Madanmohan, Sethuraman, & Narayan, 2005). As blood pressure
increases further with chronic hypertension, baroretlex sensitivity will continue to decrease
(Pikkujamsa et aI., 1998). This is of clinical importance since reductions in HRV and BRS
have been associated with increased mortality and morbidity and an increase in the
prevalence of cardiovascular diseases (La Rovere, Specchia, Mortara, & Schwartz, 1988;
Nishiue et aI., 1999; Singh et aI., 1998; Tsuji et aI., 1996). It is believed that the decrease in
BRS is a cause and maintaining factor of hypertension (Overhaus et aI., 2003).
As mentioned earlier, exercise provides an antihypertensive hemodynamic effect
(Arakawa, 1993; Arroll & Beaglehole, 1993; Kelley & McClellan, 1994; Martin et aI., 1990).
These changes in blood pressure may be associated with changes in autonomic function
which is controlled within the higher centers of the brain through the division of
parasympathetic (vagal modulation and decrease in heart rate) vs. sympathetic (increase in
heart rate) branches of the nervous system. It has been shown that cardiovascular autonomic
modulation and blood pressure can be improved with exercise training in pre-hypertensive
individuals (Collier et aI., 2009; Ketelhut, Franz, & Scholze, 2004; Lucini et aI., 2002;
Timmers, Wieling, Karemaker, & Lenders, 2004). It is also more judicious and safer to
study pre-hypertensive individuals during exercise training since they have less risk factors,
yet their hemodynamic responses liken that of hypertensives where we would extrapolate the
results.
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The structure of the vasculature does not determine arterial stiffness by itself; the
endothelium releases vasoactive substances such as nitric oxide (NO) and endothelin
(Cockcroft et aI., 2000). Some other mechanisms of post exercise hypotension are mediated
by adenosine and the alteration of sympathetic outflow (Boone & Corry, 1996). Boone &
Corry (1996) showed that NO acts as a powerful vasodilator which can reduce vascular
resistance to blood flow, thus decreasing blood pressure, and is upregulated following
exercise.
Shear stress and pressure on the endothelium lead to signaling of vasodilators such as
nitric oxide (NO), prostacyclin (PGh), and endothelium-derived hyperpolarizing factors
(EDHF) (Rush & Ford, 2007). NO is a vasodilator and its bioavailability is dependent on its
synthesis and destruction. Endothelial nitric oxide synthase (eNOS) is prevalent in the
endothelium and myocardium and generates NO when stimulated by physical and chemical
factors, such as shear stress and Angiotensin II (Ang II) (Izzo, Sica, & Black, 2008). NO
must then diffuse to vascular smooth muscle to cause relaxation and dilation of the blood
vessel, decrease vascular resistance and increase blood flow. NO induced endothelium
dependent relaxation has a direct vasodilatory effect on the surrounding smooth muscle, but
NO also has several indirect vasodilatory effects such as the downregulation of Ang II,
counteracting agonist-induced vasoconstriction and the inhibition of endothelin-l, a powerful
vasoconstrictor. The inhibition of NO upregulates Angiotensin Converting Enzyme (ACE),
increases Ang II, increases a toxic free radical, superoxide (02-), and induces
vasoconstriction, which ultimately leads to hypertension (lzzo, Sica, & Black, 2008). NO
can also be degraded when it interacts with ROS. Several studies have shown that in
sedentary individuals, there is a higher presence of reactive oxygen species (ROS) which has
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been shown to decrease NO (Barton et ai., 200 I; Eiserich et ai., 1995). Normally, cells are
protected from ROS damage by enzymes like superoxide dismutase (SOD) and antioxidants
prevent ROS damage by scavenging free radicals. Under normal conditions, ROS are
produced in low concentrations and regulate vascular homeostasis, but in hypertensive
individuals, there is an elevation in ROS which decreases NO bioavailability and. leads to
vascular dysfunction (Rush & Ford, 2007).
Exercise and oxidative stress
Reactive oxygen species (ROS), reactive nitrogen species (RNS) and their by-
products are termed free radicals and have been linked to premature vessel aging and disease
by modifying cellular components (Ooto, Naito, Kaneko, Chung, & Radak, 2007). ROS are
composed of two main groups: free radicals and nonradicals. Free radicals such as
superoxide (02"), hydroxyl (OH) and nitric oxide (NO) have one or more unpaired electrons
which contribute to the instability of the compound; while nonradicals like hydrogen
peroxide (H202), ozone (03) and peroxynitrite (ONOO-) are more stable compounds because
they do not have a single unpaired electron. Nonradicals are reduced when its electrons are
accepted into orbitals and function as a strong oxidizing agent.
The significance of superoxide production is that is can lead to the impairment of
endothelium dependent relaxation by increasing vascular oxidative stress, leading to eNOS
uncoupling and a shift to production of superoxide instead of NO by the oxidation of
tetrahydrobioprotein (BH4). ROS are scavenged by antioxidant systems such as glutathione
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peroxidase (GTP) and SOD, however when this balance is disturbed the physiological
consequence is vascular-oxidative stress (Izzo, Sica, & Black, 2008).
Free radicals, and more specifically ROS levels, increase due to inflammation
produced from an acute exercise bout. This leads to an increase of oxidative stress and
cellular damage (Goldfarb, Patrick, Bryer, & You, 2005). It has been shown that 30 minutes
of aerobic and anaerobic exercise can increase biomarkers ofoxidative stress (Bloomer,
Goldfarb, Wideman, McKenzie, & Consitt, 2005). The damage resulting from oxidative
stress has been suggested to contribute to many diseases, such as atherosclerosis, Parkinson's
disease, heart failure, heart attacks, and Alzheimer's disease (de Diego-Otero et aI., 2009).
Vascular oxidative stress is elevated in hypertensives, leading to the elevation of ROS levels
which impairs NO dependent dilation. Antioxidant therapy has been shown to buffer this
increase of ROS and therefore restore NO dependent dilation to the vasculature (Rush &
Ford, 2007). Antioxidants could protect cellular components from ROS (Goldfarb et aI.,
2005) and it has been shown that the antioxidant supplementation of Vitamin C can protect
against exercise induced oxidative stress (Goldfarb et aI., 2005). Two weeks of an
antioxidant supplement reduces exercise induced oxidative stress in both males and females
(Goldfarb, McKenzie, & Bloomer, 2007). However, most of these studies have used
vitamins, such as Vitamin C, D, or E, which have been shown to possess antioxidant
capabilities, yet have used only a single vitamin in high concentrations. This study will be
one of the first to study the effects ofa multi-flavonoid compound plus fish-oil supplement
on cardiovascular hemodynamics and arterial stiffness.
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Antioxidants
Flavonoids are strong antioxidants because of their low redox potential and capacity
to donate several electrons or hydrogen atoms. Flavonoids are found in common foods such
as onions, apples, dark chocolate, green tea, red wine, and grapefruit. Antioxidant
supplementation reduces acute exercise induced inflammation and oxidative stress, which
increases the bioavailability ofNO (Barton et aI., 200 I; Eiserich et aI., 1995; Forstermann et
aI., 1998; Kingwell, 2000). It has also been shown that antioxidant supplementation is
beneficial in offsetting the negative effects of vascular oxidative stress in elderly people by
increasing blood flow to skeletal muscle, thereby enhancing the benefits of exercise.
Increased blood flow and decreases in vascular oxidative stress has been shown to reduce
cardiovascular risks by further decreases in blood pressure (Galan et aI., 2006).
Quercetin
Quercetin is a plant-derived flavonoid commonly used as a nutritional supplement
and is found in foods such as onions, apples, red wine, broccoli and tea (McAnulty et aI.,
2008). Laboratory studies show that quercetin may have anti-inflammatory and antioxidant
properties, and it is currently being investigated for a wide range of potential health benefits
(Davis, Murphy, Carmichael, & Davis, 2009; Stewart et aI., 2008). There is also research
that has been done that suggests that quercetin reduces blood pressure in hypertensive
subjects (Edwards et aI., 2007). In rat models, severe oxidative damage produced from
swimming was decreased due to quercetin supplementation, showing that quercetin may be
effective for the prevention and treatment of oxidative damage (Haleagrahara,
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Radhakrishnan, Lee, & Kumar, 2009). In a recent study, supplementation of quercetin plus
Vitamin C was shown to increase plasma quercetin levels but have no influence on oxidative
stress or antioxidant capacity measures (Shanely et aI., 2009). Chronic quercetin ingestion
has not been proven to protect against exercise induced oxidative stress or inflammation
(McAnulty et aI., 2008). However, the supplement used in the present investigation was a
mixture of several antioxidants and multi-flavonoids in addition to quercetin, which may
have a synergistic effect resulting in a decrease in oxidative stress, leading to an upregulation
of NO which in turn augments vasodilation and decreases blood pressure.
EGCG
EGCG (epigallocatechin 3-gallate) or green tea extract, has beneficial effects on
cardiovascular and metabolic health and it has been suggested that EGCG may contribute to
the maintenance of health and treatment ofdiseases (Wolfram, 2007). EGCG also decreased
stroke and mortality in stroke-prone, spontaneously hypertensive rats (Uchida et aI., 1995).
In relation to blood pressure, EGCG has been shown to decrease systolic blood pressure and
enhance endothelial function and insulin sensitivity of spontaneous hypertensive rats. It also
decreased infarct volume and improved ventricular function after ischemia reperfusion
(Potenza et aI., 2007).
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Fish Oil
Fish oil has been shown to have many benefits concerning cardiovascular health. It
was first researched when the Greenland Inuits, who have a diet high in n-3 polyunsaturated
fatty acids (like fish oil) were found to have low mortality from cardiovascular disease (Leaf,
Kang, & Xiao, 2008). People with a high risk of ischemic heart disease and/or hypertension
could benefit from eating fish as clinical trials have shown that undergoing supplementation
of farty acids like fish oil can improve arterial elasticity in subjects with diabetes or
dyslipidemia and even improved large arterial elasticity in overweight hypertensive patients
(Wang et aI., 2008). A combination of fish oil and aerobic exercise has been shown to be
more effective compared with separately to decrease triglycerides, increase high-density
lipoprotein (HDL) and improve endothelium dependent arterial vasodilation (Hill, Buckley,
Murphy, & Howe, 2007). However, results from fish oil students are equivocal. A study by
Lofgren, et al. (1993) found no change from pre-supplementation in systolic or diastolic
blood pressure.
Because quercetin, EGCG, and fish oil have shown positive effects on arterial health
separately, it is possible that a combination could be more effective on vasculature
parameters such as PWV, an increase in vasodilation leading to a decrease in blood pressure.
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Measurements of Antioxidant Capacity
FRAP and ORAC Assays
The Ferric Reducing Ability of Plasma (FRAP) assay measures the ferric
reducing ability within the blood in the presence of antioxidants whereas the Oxygen Radical
Absorptive Capacity (ORAC) assay measures the capacity of an antioxidant to directly
reduce free radicals. The ORAC assay has a high sensitivity for the absorbed oxygen
radicals and provides considerable information concerning the antioxidant capacity of
biological samples such as melatonin, dopamine, and flavonoids, as well as tea, fruits,
vegetables, and animal tissues (Cao & Prior, 1998).
There is little correlation between the ORAC and FRAP assay because they use
different methodologies of determining antioxidant capacity. ORAC uses an inhibition
method in which a blood sample is added to a system that generates free radicals, the
inhibition of the free radical action is calculated and related to the antioxidant capacity of the
sample. FRAP, however, uses no free radicals or oxidants in the assay (Cao & Prior, 1998).
Therefore, ORAC measures the inhibition of free radicals generated and the FRAP assay uses
antioxidants as reductants in a redox-linked reaction to determine the total antioxidant power
of the blood.
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Summary
Hypertension is a serious yet treatable condition. However, if it remains untreated, it
can lead to many health problems, cardiovascular disease and a decreased life span.
Currently, the most common treatment is medication, which can lead to multiple side effects
or can interact negatively with other medications. It is apparent in the literature that exercise
leads to a decrease in blood pressure which can be effective in treating hypertension.
Antioxidants have been shown to increase NO, which in tum increases vasodilation, which
leads to a decrease in the pressure of blood traveling through the arteries. A combination of
PEH and the anti-hypertensive effects of antioxidants could possibly lead to an effective
treatment for hypertensives that does not require medication. Assuming this treatment is safe
and effective in a young population, the research problem would then be applied to a
hypertensive population. This research is important due to the issues that hypertension
presents both socially and economically.
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Chapter 3
Methodology
Subjects
Twenty subjects (2 females and 18 males) were recruited in the age range of 18-26
years and were moderately active as classified by Ainsworth et al. (1993). Subjects were
recruited through posters/fliers located throughout the University. During initial screening,
subjects were asked about any known cardiovascular disease, with special emphasis on
sudden cardiac death in any young first, or second degree relatives. Subjects with any such
family history were excluded. Any subject with known cardiovascular disease, diabetes,
hypertension, or currently taking any medication, including birth control and aspirin, was
also excluded. Procedures were reviewed by Appalachian State University's Internal Review
Board. All subjects read and signed informed consent forms to show willingness to
participate in the research study and were allowed to withdraw at any time.
Research Design
Subjects underwent a total of four visits, as outlined below:
Visit I consisted of lab familiarization, informed consent, a graded exercise test
performed on a treadmill to determine VOZpeak, and a body composition assessment. The
subjects underwent a fasting blood draw on their second visit.
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Upon entering the laboratory for Visit 3, subjects were seated for 5 minutes and had a
resting blood pressure taken in their left arm using a manual sphygmomanometer and a
stethoscope, as well as pulse wave analysis measurements. The subjects then rested in a
supine position while pulse wave velocity measurements were taken, after which the subjects
were left in a quiet, darkened room for 10 minutes while beat to beat blood pressure
measurements were recorded. After beat to beat measurements, the subjects underwent a
pre-exercise blood draw, followed by a run on the treadmill at 65-70% of their V02peak for 30
minutes. Immediately following completion of exercise, a second blood draw was performed
and then a seated manual blood pressure and pulse wave analysis measurements were
obtained. Finally, the subjects were placed in a supine resting position and had PWV and
beat to beat BP measurements. All above described measurements were repeated 30 minutes
following exercise.
After the third visit, the subjects started on a fourteen day supplementation ofan
antioxidant mixture of quercetin, omega-3, and EGCG or a placebo, which was similar in
composition and taste but without the active ingredients. The daily dose of four treatment
supplements provided 1000 mg quercetin (Q) with 120 mg epigallocatechin 3-gallate
(EGCG), 400 mg isoquercetin, and 400 mg omega-3 fatty acids from fish oil (Q-EGCG).
The subjects were instructed to take four doses a day, with two taken in the morning and two
taken in the evening. Once the fourteen day supplementation was completed, the subjects
reported back to the lab within 24 hours for their fourth and final visit. The procedures for
the fourth visit were identical to the third visit, except they were post-supplementation.
The female subjects had to arrange their supplementation and visits around their
menstrual cycle to control for fluctuating hormones, due to the cardioprotective effect of
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estrogen. Both Visit 3 and 4 were perfonned between day I and day 5 of their menstrual
cycle. Following visit 3, supplementation was withheld in an attempt to allow visit 4 to
occur between day 1 and 5 of their cycle. Retrospectively, both female subjects were tested
at Visit 3 and 4 on the second day of their menstrual cycle.
Analyses: Biomarkers of Oxidative Stress
Fasted blood samples were drawn from an antecubital vein with subjects in a seated
position. The blood samples were centrifuged in sodium heparin or EDTA tubes, and plasma
was aliquoted and then stored at -80a C prior to analysis for plasma antioxidant parameters
(FRAP and ORAC).
FRAP
Total plasma antioxidant potential was detennined by the ferric reducing ability of
plasma (FRAP) assay according to the methodology of Benzie and Strain (1996). The
general principle of this assay is that water soluble reducing agents (antioxidants) in the
plasma will reduce ferric ions to ferrous ions, which then react with an added chromogen.
Samples and standards were analyzed in duplicate and expressed as ascorbate equivalents
based on an ascorbate standard curve (0-1000 !J.mol). Intra-assay and inter-assay coefficients
of variation were less than 5% and 7%, respectively.
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ORAC
The ORAC assay was performed on a microplate reader using a modification of the
methodology ofOu et at. (2001). The ORAC assay is based upon the inhibition of the
peroxyl-radical-induced oxidation initiated by thermal decomposition of azo-compounds
such as 2,2'-azobis(2-methylpropionamidine) dihydrochloride (AAPH). Briefly, trolox
standards were made from a trolox stock solution. A serial dilution of a 50 JlM trolox
solution was made with phosphate buffer solution to produce 25, 12.5,6.25 JlM trolox
standards. A fluorescein (Aldrich Chemicals, St.Louis, MO) working solution was made by
pipetting 800 JlL of stock solution into 50 mL phosphate buffer in a 50 mL conical tube.
Before use, the solution was incubated in the water bath at 37°C until thoroughly heated.
The AAPH solution was made by dissolving 0.108 g of AAPH (Wako Chemical) into 5 mL
of incubated phosphate buffer immediately before the start of the assay. The microplate was
prepared and loaded in a "forward-then-reverse" order to avoid possible positional errors.
The edge wells were left empty or blank (phosphate buffer working solution) to reduce the
impact of "edge effect" on samples and standards particularly from temperature effects on
the outside wells. Twenty JlL of sample, blank, and trolox standard solutions were pipetted
into appropriate wells. Then, 200 JlL fluoroscein working solution were added to each well
using an 8 channel micropipettor. A cover was placed on the microplate and the plate and
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contents incubated at 37 C for at least 20 minutes. Then, 20 JlL AAPH working solution
were added using an 8 channel micropipettor as quickly as possible. Final ORAC values
(uM/L trolox) were made from the plate reader derived area under the curve (AUC). Then,
the final ORACFL values were calculated by using a quadratic regression equation x =
-b ± Jb2 - 4ac + 4cy. Excitation wavelength was 485 nm and emission wavelength was
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520 nm. Intra-assay and inter-assay coefficients of variation were less than 5% and 7%,
respectively.
Procedures
Visit 1
Dual Energy X-ray Absorptiometry (DEXA). Body composition was assessed determined
using a DEXAscan. The subject laid in a supine position on the DEXA scan table while a
low dose X-ray scanned the full body.
VOzpeak exercise testing. Peak oxygen consumption was assessed using a progressive
exercise test performed to fatigue on a motor driven treadmill. The subject began the test on
a level treadmill at a comfortable running pace (between 5.0 and 6.0 miles per hour) with the
incline increasing 2.5% every two minutes until volitional fatigue was reached. If the subject
did not reach fatigue after 2 minutes at a treadmill grade of 10%, the speed was then
increased by 0.5 mph every minute. Heart rate was measured using a Polar Heart Rate
Monitor (Polar Electro, Inc., Woodbury, NY, USA) and was recorded at the end of each
stage, along with RPE. Expired gases were analyzed using a Quark b2 breath-by-breath
metabolic system (Cosmed, Rome, Italy). Maximal effort was considered to have been
reached when subjects met three of the following four criteria: a) an RER of 1.15 or greater;
b) a plateau in HR despite an increase in workload; c) a final RPE score of 17 or greater on
the Borg scale (scale 6-20); and/or d) a plateau in oxygen uptake despite an increase in
workload.
26
Visit 3 and Visit 4
Pulse Wave Velocity (PWV). All measurements were conducted in accordance with
guidelines set forth by the Clinical Application of Arterial Stiffness, Task Force III. A
pressure tonometer was used to transcutaneously record the pressure pulse waveforms in the
underlying artery. The pressure pulse waveform was recorded simultaneously with an ECG
signal, which provided an R-wave timing reference. Pressure pulse recordings were
performed consecutively at two superficial artery sites. The tonometer was used to obtain the
pulse wave between: (1) left common carotid artery and the left femoral artery, and (2)
between the left femoral and the left dorsalis pedis artery. Distance from the carotid
sampling site to the midpoint of the manubrium sterni, manubrium sternum to femoral artery,
and femoral artery to dorsalis pedis was measured between these points as straight lines with
a tape measure. The distance from the carotid artery to the manubrium sterni was subtracted
from the manubrium to femoral artery distance. PWV was determined from the foot-to-foot
.,
flow wave velocity. The foot of the pressure wave was identified visually as the point of
systolic upstroke. The time delay between a minimum of 15 simultaneously recorded flow
waves was averaged. PWV was then calculated using the mean time difference and the
arterial path length between the two recording sites as follows: PWV = D / t (m/s); where D
is distance in meters and t is the time interval in seconds. Values attained from carotid to
femoral artery were taken as an index of central compliance while values attained from the
femoral to dorsalis pedis were taken as an index of peripheral compliance. All data were
stored and analyzed off-line after completion of testing.
Hemodynamic Monitoring. Beat-to-beat blood pressures were determined via the
Finometer (FMS, Amsterdam, The Netherlands). With subjects in a supine position in a
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quiet and darkened room, beat-to-beat blood pressures were recorded for 10 minutes via
finger plethysmography. This noninvasive measurement of the change in blood pressure has
been shown to be reliable when compared with measurements of intra-arterial blood pressure
(lmholz, Wieting, Langewouters, & van Montfrans, 1991). The brachial blood pressure was
obtained using an integrated brachial blood pressure cuff and brachial BP waveforms were
reconstructed from finger arterial waveforms by applying an inverse transfer function, a
waveform filter, a level correction, and a level calibration (Guelen et aI., 2003). This has
been shown to increase the correlation between finger and proximal arterial blood pressure
values, allowing pressure values to remain within the American Association for Medical
Instrumentation (AAMI) standards for the evaluation ofautomated sphygmomanometers
(Parati et aI., 2003).
Supplementation. Using a double blind methodology, supplementation was provided to the
20 subjects, with 10 subjects ingesting the supplement and 10 ingesting the placebo.
Supplement and placebo were provided in a chew form for 14 days, with two chews taken in
the morning and two chews taken in the evening. The total daily dose of the active ingredient
was 1000 mg quercetin (Q) with 120 mg epigallocatechin 3-gallate (EGCG), 400 mg
isoquercetin, and 400 mg omega-3 fatty acids from fish oil (Q-EGCG).
Statistical analysis
A pairwise I-test was employed to determine if there were differences between
subject characteristics. A 3 x 2 way ANOVA with repeated measures (time [baseline vs. pre
vs. post] by group [trt vs. placebo]) was performed on all dependent variables. If a
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significant interaction was found then the measures were followed with a Bonferroni post-
hoc test. Statistical analysis software (SPSS, Version 17.0; SPSS, Inc., Chicago, IL) was
used with a significance level ofp :s 0.05.
Results
Subject characteristics are presented in Table I. No significant differences were
found in PWV (central or peripheral), resting SBP, DBP, heart rate (HR) or ORAC between
groups. As seen in Figure I, significant differences were found in 30 minute post exercise
systolic blood pressure measurements following supplementation in the post exercise. As
shown in Figure 2, Alx also showed a significant reduction following supplementation. In
Figure 3, a significant increase was shown in FRAP in the supplementation group in the pre-
exercise measurements. Following exercise, there were no significant differences in FRAP
levels in supplement or placebo groups.
Table 1: Participant characteristics
Variable Treatment Placebo
N 10 10
Age (yr) 21.6 ± 0.62 20.7 ± 0.30
Height (cm) 177.4 ± 2.08 177.3 ± 2.57
Body mass (kg) 76.05 ± 3.24 75.55 ± 6.05
Peak oxygen consumption (ml/kg/min) 53.9 ± 3.88 47.9±3.01
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Figure 1: SBP Change: Pre to post exercise and pre to post supplementation
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Discussion
Results from the present investigation support the theory that ingesting a multi-
flavonoid plus fish oil supplement in combination with aerobic exercise significantly reduces
SSP 30 minutes post-exercise, AIx, and significantly increases resting levels of FRAP in post
supplementation levels compared with pre-supplementation.
The attenuation of Alx, a measure linked to aortic arterial stiffness, was likely due to
the significant increase in FRAP which may have led to greater expression of NO within the
elastic modulus of the aortic vessel. Since the amount of reflected wave was decreased, the
amount of elastic "cushion" had to be augmented to absorb the pulsatile bolus of blood being
ejected from the left ventricle. The increased expression of NO following flavonoid and fish
oil supplementation has been shown in many aforementioned studies. However, It was
interesting to note that despite the decrease in AIx, there was no decrease in PWV as both are
considered to be indicators or measures of arterial stiffness. This finding is not surprising
since it has been shown on several occasions that Alx is not proportional to PWV in systolic
hypertension, but is inversely related (lzzo, Sica, & Black, 2008). In one study by Vyas et al.
(2007), AIx was inversely related to aortic PWV and weakly related to aortic compliance and
an increase in AIx is not a reliable replacement for increased aortic stiffness. However, it did
show that higher stiffness (increased PWV and lower compliance) was associated with a
lower Alx (Vyas et aI., 2007). The increased distensibility that resulted in a more favorable
augmentation index could be due to the composition of the matrix of the vessel. The aorta
has been shown to have the largest amount of eNOS potential and the supplement may have
the greatest potential to upregulate this synthase pool.
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Although the antioxidant supplementation did not have any effect on vascular
distensibility (PWV) or resting SBP, the magnitude of PEH was significantly decreased in
the 30 minute post exercise period after supplementation for the treatment condition when
compared to the placebo without showing a correlating decrease in HR or PWV. Although
resting SBP did not change with supplementation, there was a significant decrease in the
systolic component ofPEH. Because there was no change in PWV, one can only postulate
that arterial distensibility was not the cause of this reduction in blood pressure. One possible
explanation is that the supplementation caused a decrease in oxidative stress, potentially due
to an increase in antioxidant power (increase in FRAP). A reduction in ROS would increase
the bioavailability of NO, stimulating vasodilation. A second theory would be a change in
sympathovagal regulation in which the supplement may induce a sympatho-Iysing effect on
sympathetic tone, thereby increasing the vagal tone.
The results of the present investigation support research done by Edwards et al.
(2007) who demonstrated a reduction in resting blood pressure in hypertensive versus pre-
hypertensive patients following an antioxidant supplementation regimen of quercetin. Many
studies have shown a beneficial decrease in resting blood pressure in hypertensives, showing
the possibility that this decrease in blood pressure can affect the hypertensive patient but not
a normotensive or pre-hypertensive patient. This also supports research demonstrating that
antioxidants (like quercetin and Vitamin C) increased plasma quercetin levels but had no
influence on oxidative stress or antioxidant capacity measures (Shanely et aI., 2009) and that
chronic quercetin ingestion does not protect against exercise induced oxidative stress or
inflammation (McAnulty et aI., 2008). Without this protective mechanism against oxidative
stress, it is possible that NO was not increased. Much of the research concerning antioxidant
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use has been shown to have beneficial effects in animal models (Duarte, Galisteo et a\., 200 I;
Duarte et aI., 2002; Duarte, Perez-Palencia et aI., 2001; Duarte, Perez-Vizcaino, Zarzuelo,
Jimenez, & Tamargo, 1993, 1994; Haleagrahara et a\., 2009; Ibarra et a\., 2003; Ibarra et a\.,
2002), but there is a lack of benefits shown in human models. This is potentially because the
dosages ingested are not large enough to induce any benefits physiologically and because in
large quantities, most antioxidants are not able to be absorbed and are simply excreted out.
The significant increase in FRAP in the treatment group demonstrates that the total
plasma antioxidant capacity increased following supplementation which may be related to
the further decrease in systolic blood pressure during the post-exercise period. This increase
in antioxidant capacity could lead to an increase of free radical scavenging by antioxidants,
thereby decreasing oxidative stress and potentially increasing NO levels. An increase of NO
in the vasculature would lead to vasodilation and a further decrease of the systolic blood
pressure post exercise. Interestingly, resting blood pressure following two weeks of
supplementation was unchanged, demonstrating that a decrease in blood pressure in the 30
minute post exercise period from antioxidant supplementation occurred in conjunction with
post exercise vasodilation.
Figure Legends
Figure I. The change in systolic blood pressure from pre and post exercise for Visit 3 (pre
supplementation/placebo) and Visit 4 (post supplementation/placebo) amongst the trt group
(n=lO) and the placebo group (n=IO). Values are means ± SEM. Figure 2. Augmentation
index pre and post exercise for visit 1 (pre supplementation/placebo) and visit 2 (post
supplementation/placebo) for Trt group (n=IO) and placebo group (n=IO). Values are means
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±SEM. Figure 3. FRAP assay results pre and post exercise for Visit 3 (pre
supplementation/placebo) and Visit 4 (post supplementation/placebo) amongst the trt group
(n=10) and the placebo group (11=10). Values are means ± SEM.
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Consent Form
Appalachian State University
Consent / Authorization Form
Title of Study: Changes in vascular and hemodynamic parameters following acute exercise
and antioxidant supplementation
Background/Purpose:
You are being asked to participate in a research study because you are a healthy person
between 18 and 24 years of age, with no diabetes, kidney or heart problems, no history of
stroke and no other known cardiovascular risk factors. Scott Collier, PhD (Department of
Health, Leisure and Exercise Science at Appalachian State University) is conducting this
study.
The purpose of this study is to examine the potential methods of modulating blood pressure
response to aerobic exercise training. In addition we are interested in examining how aerobic
exercise affects your body's ability to change blood pressure, heart rate and blood vessel size.
During exercise, it is important for your arteries to be able to expand to let more blood tlow
through them to get to the working muscles. We know that ccrtain biologicalmolccules
modulate this distensibility. This may also depend upon the level of readive oxygen species,
henceforth, referred to as ROS, in the vessel wall. We would like to investigate the eftcds of
an antioxidant molecule, commonly known as a mixed tlavanoid, in modulating vascular
response after an acute bout of aerobic excrcise.
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The purpose of this research study includes:
General:
Specific:
Study the effects of an antioxidant molecule, commonly known as a
tlavonoid, in modulating vascular response aller an acute bout of aerobic
exercise. Each supplement contains 1000 mg quercetin (Q) with 120 mg
epigallocatechin 3-gallate (EGCG), 400 mg isoquercetin, and 400 mg omega-
3 fatty acids from fish oil (Q-EGCG), and was formulated and tested in
collaboration with Quercegen Pharma (Newton, MA). The supplement has
been shown to decrease the reactive oxygen species in the blood which can
lead to a decrease in mean blood pressure and increase the rate at which your
kidneys filter blood.
To assess the changes in blood vessel stiffness/expandability following an
acute bout of aerobic training before, and after 2 weeks of oral tlavanoid
supplementation.
If you have a known cardiovascular heart disease, such as congenital heart disease,
hypertrophic cardiomyopathy, complex supraventricular or ventricular dysrhythmias at rest
or dysrhythmias that worsen with exercise, this study is not appropriate for you. The
remainder of this form will explain the study in greater detail. If you have any questions, feel
free to ask.
Study Procedures:
If you choose to participate, you will be asked:
I. To report to the Human Performance Laboratory at Appalachian State University
(Room 054 of the Holmes Convocation Center) on 3 separate occasions for about I to
1.5 hours per visit for a blood draw, hemodynamic and exercise measures.
At visit J (Initial visit)
During this visit, you will be familiarized to the study instruments and procedures in the
Human Pertormance Laboratory at Appalachian State University. 1\11 tests will be completed
in the Human Pertonnance Laboratory, room 054 of the Ho/mes Convocation Center at J II
Rivers Street, Appalachian State University. You will be askcd to answer a medical and
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exercise history questionnaire. Then we will measure your height, weight and percentage
body fat and evaluate your cardio-respiratory fitness.
Blood Draw: We will draw approximately 20 011 of blood to use for the detection of
tlavonoids and reactive oxygen species concentrations. A trained technician will draw the
blood.
Percentage body fat: Your present body fat will be measured using the DEXA scan. You
will be lying comfortably on a cushioned bed wearing shorts and a t-shirt while the DEXA
estimates your body's composition of fat and muscle.
Graded exercise test: You will be evaluated for cardio-respiratory fitness using the graded
exercise test on a treadmill. In this test, you will start jogging on a treadmill at about 5 to 6
miles per hour and every 2 minutes the speed or grade will be increased slightly until you get
tired. This test is designed to make you tired in about 10 to 12 minutes. You will be wearing
a facemask (so that we can collect and analyze your expired air) and a heart rate monitor to
measure your heart rate. This test will determine your maximum oxygen consumption (V02)
which is your ability to take oxygen out of the air, to the working muscles. This will help us
determine the correct starting point for your aerobic exercise prescription.
You will also be familiarized with other equipment in the laboratory necessary to make the
measurements of pulse wave velocity, reactive hyperemia, and blood pressure.
At visit 2-3
At the second visit, you will be asked to undergo all of the above testing noted above. This
helps us to establish good baseline measures for you. Then you will be subjected to an acute
bout of aerobic training at 65% of your maximum capacity for 30 minutes as determined
during the first visit. At the end of exercise pulse wave velocity, reactive hyperemia, and
beat-to-beat variation of blood pressure will be measured again. Aller completion of this
session you will be asked to ingest 4 sott chews of the flavonoid supplement orally to equal a
dose of 1000 mg/day for 2 weeks, and then return to lab for the 3"J and final visit.
The various measurements during visit 2 will be as follows:
I) Pulse Wave Velocity-A small sensor resembling a pen is placed over your carotid
artery (side of your neck) and over the femoral artery (top of your leg). A transducer (like a
microphone) uses ultrasound waves (sound waves which bounce off the blood in the blood
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vessel) to measure the speed and direction of blood !low through an artery. No physical
discomfort should be experienced during this test. Your privacy will be upheld with great
care during the assessment of the femoral artery, as this is best located near the pubic area.
There are no known risks associated with the Doppler ultrasound used in this technique.
2) Occlusion test of the forearm-This test measures blood flow through your forearm. A
blood pressure cuff is placed on your upper arm, and a smaller cuff around your wrist. The
upper cuffwill be inflated to a pressure above your systolic blood pressure (the first number
when a doctor reads your blood pressure) and remain inflated at this pressure for
approximately five minutes. The wrist cutfwill be inflated to a pressure above your systolic
blood pressure one-minute before the five-minute time period has lapsed. After five minutes,
the upper cuff pressure will be released quickly. An elastic strap with a sensor placed on the
lower part of the same arm will measure the blood volume changes in your arm after the cuff
pressure has been released. Once the cuff has been released we will measure changes in
blood volume in the arm for three minutes, while maintaining the wrist cuff pressure above
the systolic blood pressure. Upon completion of this three-minute time period, the wrist cuff
pressure will be released.
3) Blood Pressure Assessment - Systolic and diastolic blood pressure will be measured
using the Portapres. This technique uses a tiny cuffwom around your middle finger that can
measure blood pressure on a heart beat-to-heart beat basis.
Visit 3
The components of visit 3 will be identical to those of visit 2.
Risks:
The risks and discomforts involved with participating in this study are:
Exercise testing and training: The risks associated with exercise testing and training
include increased blood pressure and possible heart arrhythmias (abnormal heart beats).
There is a very small risk of a heart attack during the exercise testing and training. To
minimize this risk, we will have you answer questions regarding your medical history and
family history to screen for any signiticant heart disease that might exist asymptomatically.
Although, the electrocardiogram (EKG) poses minimal risk, occasionally a person is
allergic to the adhesive on the electrodes and may develop a local skin irritation.
Individuals may experience localized fatigue during the exercise testing/ training, and
possibly some muscle soreness atter the exercise testing/training. This should subside within
24-48 hours alter testing. Soreness is rare in normal, healthy individuals. Rest breaks will he
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incorporated into the training to help minimize possible soreness associated with exercise
training. We will also try to minimize this risk by taking you through a series of light
stretches after testing is completed.
Another possible risk may be abnormal changes in your heart rate and blood pressure.
We will attempt to minimize this risk by carefully monitoring your heart rate and blood
pressure responses during aerobic training.
DEXA testing: The DEXA machine is used to assess body composition. This technique is
safe, however subjects are exposed to very small amounts of radiation. The radiation
equivalent is equated to an individual taking a flight from the East coast to the West coast,
very minimal. A trained operator will be present to conduct the test and can help minimize
exposure by using the shortest test time possible.
Pulse-wave velocity: There are no known risks associated with the Doppler ultrasound used
in this test. No physical discomfort should be experienced during this test. Again, your
privacy will be upheld with great care during the assessment of the femoral artery, as this is
best located near the pubic area.
Occlusion test of the forearm: You may feel discomfort during the occlusion as your arm
may fall asleep, which is similar to the 'pins & needles' feeling you may have experienced
when a limb (e.g. leg, hand, foot) fell asleep. This feeling will be alleviated almost
immediately when the pressure cuff is released allowing normal blood flow to return. It is
possible that you may find this test painful. We can stop the test if this occurs. Rarely does
this procedure cause bruising.
Blood pressure assessment: There may be slight discomfort due to pressure felt in the
finger that the cuff is placed on. However, this slight pressure is only felt for about one
minute while the measurement is being taken.
Blood Draw: The subject may experience slight discomfort and bruising associated with the
blood draw, however we will use trained technicians to minimize the risk of discomfort and
bruising.
The investigators involved in this project have extensive experience in exercise testing,
which should minimize the above risks.
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Blood drawine: It may cause pain and/or bruising at the location on your arm where the
blood was taken. On rare occasions, it may cause lightheadedness or fainting and an
infection.
Answerine Questionnaires: should not pose any risk to you.
The investigators involved in this project have extensive experience in exercise testing,
which should minimize the above risks.
Benefits:
You will benefit from having a personal fitness assessment which will give you information
about your current aerobic fitness level. Additionally, you will receive information on how
well your heart and blood vessels respond to exercise.
The information learned may also help others in the future.
Voluntary Participation:
Your participation in this study is entirely voluntary and you may refuse to participate or
discontinue participation at any time without penalty or loss of benefits to which you would
nonnally be entitled. Your decision about whether or not to participate in the study will not
affect your relationship with Appalachian State University or The Watauga Medical Center.
Alternatives:
You are free to choose not to participate in this study.
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Costs/Payments:
There are no costs to you and/or your insurance carrier for participating in this study. You
will not be paid for your participation. In addition, you will not be reimbursed for any
parking costs incurred, however all efforts will be made to measure and train you after hours
where no parking ccsts will be incurred.
Questions:
If you have any questions about the research, or in the event of a research-related injury,
please contact Scott Collier, PhD at (828) 262-7145. If you have any questions about your
rights as a research subject, please contact Jay Cranston, M.D. at the Appalachian State
University Institutional Review Board Office at (828) 262-2692.
In Case Oflniury:
In the event of illness or physical injury resulting from taking part in this research study,
medical treatment will be provided at Watauga Medical Hospital. You will be responsible for
any costs not paid by your insurance company. No other compensation is offered by
Appalachian State University. We have no plans to give you money if you are injured. You
have not waived any of your legal rights by signing this form.
Confidentiality of Records and Authorization to Use/Share Protected Health
Information for Research:
!fyou agree to participate in this research, identifiable health inf()fJnation about you will be
llsed and shared with others involved in this research. For you to be in this research we need
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your pennission to collect and share this information. Federal law protects your right to
privacy concerning this infonnation.
When you sign this consent fonn at the end, it means that you have read this section and
authorize the use and/or sharing of your protected health information as explained below.
Your signature also means you have received a copy of Appalachian State Universities
Notice of Privacy Practices.
Individually identifiable health infonnation under the federal privacy law is considered to be
any infonnation from your medical record, or obtained from this study, that can be associated
with you, and relates to your past, present, or future physical or mental health or condition.
This is referred to as protected health infonnation.
Your protected health infonnation will be kept confidential. Your identity will not be
revealed in any publication or presentation of the results of this research.
Why is it necessary to use/share your protected health information with others?
The main reason to use and share your health infonnation is to conduct the research as
described in this consent fonn. Your information may also be shared with people and
organizations that make sure the research is being done correctly, and to report unexpected or
bad side effects you may have.
In addition, we may be required by law to release protected health information about you; for
example, ifajudge requires such release in a lawsuit, or if you tell us of your intent to harm
yourself or others.
What protected health information about you will be used or shared with others as part
of this research?
We may lise and share the results of tests, questionnaires, and interviews. We may also use
and share information from your medical and research records. We will only collect
infornlation that is needed for the research.
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Who will be authorized to use and/or share your protected health information'?
The researchers, their staff and the staff of Watauga Medical Center participating in the
research will use your protected health infonnation for this research study. In addition, the
Appalachian State Institutional Review Board (lRB) and the Watauga Medical Centers
Institutional Review Board (lRB), committees responsible for protecting the rights of
research subjects who supervise the way the research is done may have access to your
protected health infonnation.
The researchers and their statfwill detennine if your protected health infonnation will be
used or shared with others outside of Appalachian State University for purposes directly
related to the conduct of the research.
With whom would the protected health information be shared?
Your protected health infonnation may be shared with:
• Federal agencies that supervise the way the research is conducted, such as the Department
of Health and Human Services' Office for Human Research Protections, or other
governmental offices as required by law.
• If so desired, you can request your infonnation be shared with your primary care physician
All reasonable efforts will be used to protect the confidentiality of your protected health
infonnation. However, not all individuals or groups have to comply with the Federal privacy
law. Therefore, once your protected health information is disclosed (leaves Appalachian
State University), the Federal privacy law may not protect it.
For how long will your protected health information be used or shared with others?
There is no scheduled date at which this infonnation will be destroyed or no longer lIsed.
This is because information that is collected for research purposes continues to he used and
analyzed for many years and it is not possible to determine when this will be complete.
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Can you withdraw your authorization to collect/use/share your protected health
information?
You always have the right to withdraw your pennission (revoke authorization) for us to use
and share your health infonnation, by putting your request in writing to the investigator in
charge of the study. This means that no further private health infonnation will be collected.
Once authorization is revoked, you may no longer participate in this research activity, but
standard medical care and any other benefits to which you are entitled wi II not be affected.
Revoking your authorization only affects uses and sharing of information obtained after your
written request has been received, but not information obtained prior to that time.
Even after you withdraw your pennission, Appalachian State University may continue to use
and share information needed for the integrity of the study; for example, information about
an unexpected or bad side effect you experienced related to the study.
Can you have access to your health information?
At the end of the study, you have the right to see and copy health infonnation about you in
accordance with the Appalachian State University policies; however, your access may be
limited while the study is in progress.
Consent To Participate In Research & Authorization To Use And Share Personal
Health Information:
I have read and understand the Infonned Consent and conditions of this project. I have had
all my questions answered. I hereby acknowledge the above and give my voluntary consent:
Date---------------------- -----
Subject signature
Date----------------------
Witness (Optional except for certain classes of subjects)
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Should I have any questions about this research or its conduct, I may contact:
Scott Collier at 828.262.7145 or email him at colliersr@appstate.edu
Investigator(s) Telephone/e-mail
Faculty Advisor (it applicable) Te1ephone/e-mail
Jay W. Cranston, MD
Administrator,
Graduate Studies and Research
Appalachian State University
Boone, NC 26608
828-262-2692
IRB Telephone
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irb@appstate.edu
e-mail
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APPALACHIAN STATE UNIVERSITY
Otlice Use Only__-__
REQUEST FOR REVIEW OF HUMAN I>ARTICIPANTS RESEARCH
Please type and submit one signed copy to irh((l~arpstate.cdu or mail to Research and Graduate Studies.
John E. Thomas Building.
I. Date: April 23. 2009
2. Project Title: Changes in vascular and hemodynamic parameters tollowing acute exercise and
anti-oxidant supplementation
3. Principallnvestigator(s): Scott Collier. PhD
4. Phone: (828)262-7145 Email: colliersr@appstate.edu
5. Post Office Address: 051 Holmes Convocation Center, ASU Box 32071
6. Academic Department/Unit: Dept of Health Leisure and Exercise Science
7. ASU Status: Faculty/Staffl8l Graduate Student 0 Undergraduate Student 0 Other 0
8. If student, name of faculty mentor
9. Faculty mentor's e-mail address:
Faculty Post Office Address:
10. This is: Honors or Master's Thesis 181 Capstone or Project of Learning 0
Dissertation D Faculty Research D Other
I I. Plan to publish or present off-campus: Yes 181 NoD
12. Projected data collection dates 0510 I/09 to 05/01109
13. Proposals cannot be considered until the researchers have completed the online CITI
Training (http://www.c itiprogram .org/dd~llllt.asp''1anguage=engl ish) required for
human subject research. Do the investigators have documentation of completion on tile in the IRB
Office? Yes I8l NoD
14. Does this research involve any out-of-country travel? YesD No 181
I have read Appalachian State University's Policy and Procedures on Human Subjects Research and agree
to abide them. I also agree to report and signi ticant and relevant changes in procedures and instruments
as they relate to participants to the Chairperson of the Institutional Review Board
PI
If 1'1 is student. Faculty Mentor
Date
Datc
Co-investigator
('0- investigator
Date
Datc
CHECKLIST FOR RESEARCH INVOLVING HUMAN PARTICIPANTS
I. Purpose of proposed research.
We will investigate the role of anti-oxidant flavanoid (Q-force immune, QFI) in modulating the vascular
response to resistance exercise. Anti-oxidants have been demonstrated to increase bioavailahility of NO.
We hypothesize that use of QFI with aerobic exercise will prevent or reduce the increase in core BP and
pulse wave velocity (measures of increased core BP), while maintaining vascular reactivity in brachial
arteries owing to increased bioavailability of NO.
2. Briefly describe your subject population. Will any individuals be excluded solely on the basis of
gender, race, color, or any other demographic characteristic? Ifso, please explain.
20 (10 males. 10 females) young healthy subjects (without known cardiovascular disease) in the age range of 18-24 years.
Subjects will be recruited through posterslfliers located throughout Appalachian State University and word or mouth. During
initial screening subjects will be asked about any known cardiovascular disease, with special emphasis on sudden cardiac
death in any young first, or second degree relatives. Subjects with any such family history will be excluded. Any subject wit~
known cardiovascular disease, diabetes, HTN, smoking, bony deformity, or currently taking any medication will be excludeq.
3. Give a brief description of your research procedures as they relate to the use of human participants.
This description should include, at least, the following:
• Procedures
• Name and description of data gathering instrument (attach copy, if applicable)
• How will the data be collected? (e.g., audio, video, written records)
• Sample size
• How long will the procedures take?
• What, if any, relationship exists between the researcher(s) and the participants?
• What, ifany, relationship exists between the researcher(s) and the agencies (e.g., schools,
hospitals, homes)?
• Attach statement of approval from any agencies (e.g., schools, hospitals, homes) that wi II
be involved with recruitment of participants or data collection.
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4. Is deception involved?
If yes, please describe.
YES 0 NO f8J
5. Do the data to be collected relate to any illegal activities (e.g. drug use, abuse, assault)?
YES 0 NO f8J
If yes, please explain.
6. The benefits of this activity to the participants must outweigh the potential risks. To this end,
please:
a. Describe the benefits to the individual participants and to society.
Subjects will receive information regarding their exercise capacity, body composition and fitness level.
b. Describe the potential risks to any individual participating in this project. Please
explain any possible risks of psychological, legal, physical, or social harm. What
provisions have been made to insure that appropriate facilities and professional attention
necessary for the health and safety of the participants are available and will be utilized?
In the age group selected for Ihis study. the cardiovascular complicalions are e'lremely unlikely, SuhjecIs '"..e an e'lrl'mdy low likelih.",c1 of cardiac
arrhythmia and hearl attack (myocaolial infarction), In Ihc extremely unlikely evenl of inelusion ofa suhject wilh rare syndrnmes of predisposition 10 cardiac
arrhythmia (such as Ilrugada syndrome. t\RVD. IIOCM. long ()T syndrnme ele), there would he a risk of cardiac arrhythmia. and even sudden ,'ardiac "cath,
The risk will not he any hil/her Ihan iflhal individual were to ,'xcrei", ,1II hisiher own, withoullhe knowledge of his,her underlying I",art disca,,', Tominimite
;lny such risk. all suhjccts wilh any known pre-cxisting.l'ardiovnscular disease will he excluded. ,\SCM glliuclil1~S "If cxcrdl\c le~till!! and Iraining will ~
",lIowed strictly hy Ihe inwsligalor in deleonining e,sercise cap'lCily "f suhjecls 10 minimite risks of physical injury during exercise.
BodpocJ; BnJpnd is a device that 1llC'~surcs hndy cnmpnsitinn. The nH.~asurcmcnt is wililtlut ri~k. hut may t:ausc symphlfns or c..:Iallslrnphohiil In some '\lIhj ...·cls
which may lind the device un3<ceptahle, !luring inilial ""niliaritati"n procedure ,uhjeers will he asked ahmll such issues and gil'en a chance 10 sil ill Ihe
chamher pri"r Illlesting,
Reacli"e hyperemia: Suhjecls may experience 'pins and needles' in Ihe arm heing suhjecled lolhe lesl which ,!uickly disappears once o<choding ..ulfis "el1al,'d
and hlm'H.f now rc(unlS to normal. Five l11illllh.·S nf complete pc.:dusinn is required in Ihe standard ml.:thod. No d:lIllagc 10 risSlIl' ha~ C'vt.'r b...·cl1 rcporh:d.
Pulse wa\'t: \'dtl~jty: rhis is 1llt.'4lsured h~ placing Doppler prohcs over r:IJi<..t1 ;trtery.,.:arotid ;lrfl'F)'. tt:mnral :trIer) .. Illd dnr"lali-; flo4:di, ;Irll:r)'. 'hl.' dc\il.'L' ""~.,,
1I1lraSnuI1d 10 ll1easure vehx:ily nfhl<Hld l1(lW, \.. hidl has)1o l...lltl\\'1l ddd...'ri"us t.:tll'l'l tll1li'\~IIt.'. SlIhjClt.."1 dignil~ willll\..' .... Irirlly lIrlwlti \\hik 1l1;lklll~
111t.';l~Hn:l11l'l1ts from th~ ' .... l11oral artery, gi\t1'1l thatillis \\lluld rl'ljllin: rroncs to I't.: plac~'d illl!-r"in.
7. Please describe how participants will be infonned of their rights and how informed consent
will be obtained and documented. Attach a copy of the consent form and any materials used in
the recruitment of participants.
Consent waiver, see attached
8. The confidentiality of all participants must be maintained. To this end, please respond to the
following.
a. How will the confidentiality of participants be maintained?
Like any study, participation will involve some loss of privacy, but the information collected from each su~icct will he
handled as confidentially as possible. The individuals file and hardcopy data will be locked in a file cabinet within a
locked office in a secure building and each data file will be encoded without the individuals name to associate it. The
blood samples will not have any names associated with them (decoded) prior to their packaging for shipment to the lab
where the analyses are carried out.
b. How will confidentiality of data be maintained?
The data will be coded and entered into a computer spreadsheet and all individual identifiers will be
removed.
c. Describe the process of final disposition of the data. How long will the data be stored
and how will they be destroyed?
All hardcopy data will be destroyed and the computer files will be erased 5 years following the
protocol, at which time all manuscript writing will cease.
d. How are participants protected from the future harmful use of the data collected in
this protocol?
All data will be used only for the purpose of this study and no data will be shared with anyone outside
the immediate study team. Further, all study data will be decoded so there will be no identifying
features left on the spreadsheets.
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